Parkman Healthcare Partners LLC Raises Stock Holdings in Standard BioTools Inc. (NASDAQ:LAB)

Parkman Healthcare Partners LLC boosted its position in Standard BioTools Inc. (NASDAQ:LAB) by 20.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 603,620 shares of the company’s stock after acquiring an additional 103,620 shares during the quarter. Parkman Healthcare Partners LLC’s holdings in Standard BioTools were worth $1,334,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently modified their holdings of LAB. Dynamic Technology Lab Private Ltd bought a new stake in Standard BioTools in the fourth quarter valued at $55,000. Jump Financial LLC increased its stake in Standard BioTools by 117.2% during the 4th quarter. Jump Financial LLC now owns 70,480 shares of the company’s stock valued at $156,000 after purchasing an additional 38,030 shares in the last quarter. Hollow Brook Wealth Management LLC raised its holdings in Standard BioTools by 5.0% in the 4th quarter. Hollow Brook Wealth Management LLC now owns 1,874,405 shares of the company’s stock worth $4,142,000 after acquiring an additional 88,648 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Standard BioTools in the fourth quarter worth $145,000. Finally, Citigroup Inc. purchased a new stake in shares of Standard BioTools during the 3rd quarter valued at about $550,000. 53.74% of the stock is currently owned by institutional investors.

Standard BioTools Trading Down 3.0 %

NASDAQ:LAB traded down $0.07 during midday trading on Thursday, hitting $2.26. 1,885,326 shares of the company traded hands, compared to its average volume of 2,254,837. The firm has a market capitalization of $836.02 million, a P/E ratio of -2.31 and a beta of 1.66. Standard BioTools Inc. has a 12-month low of $1.57 and a 12-month high of $3.16. The firm’s fifty day moving average is $2.55 and its 200-day moving average is $2.44.

Standard BioTools (NASDAQ:LAB) last released its earnings results on Wednesday, May 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The business had revenue of $45.54 million during the quarter, compared to analysts’ expectations of $46.50 million. Standard BioTools had a negative return on equity of 144.74% and a negative net margin of 70.98%. On average, research analysts expect that Standard BioTools Inc. will post -0.4 EPS for the current fiscal year.

Insider Buying and Selling

In other Standard BioTools news, Director Casdin Partners Master Fund, L bought 100,000 shares of Standard BioTools stock in a transaction that occurred on Monday, May 20th. The shares were bought at an average cost of $2.58 per share, with a total value of $258,000.00. Following the transaction, the director now directly owns 45,475,821 shares of the company’s stock, valued at approximately $117,327,618.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders purchased 1,102,072 shares of company stock worth $2,831,304 in the last three months. 53.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Jefferies Financial Group started coverage on Standard BioTools in a research note on Thursday, April 4th. They set a “buy” rating and a $3.25 price target for the company. TD Cowen started coverage on shares of Standard BioTools in a report on Tuesday, April 16th. They set a “buy” rating and a $3.50 price objective for the company.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.